If Mr. Kennedy is serious and has the president-elect’s support for rewriting the government’s relationship with psychedelics, here are five logical and appropriately cautious steps that will support a flourishing in psychedelic science and innovation in mental health treatments.
🧵
"Higher Highs (HH) and Lower Lows (LL) help spot market trends. Higher Lows (HL) signal a potential trend reversal to the upside when highs finish higher"
I'm starting to like the look of the $IXHL chart for the first time in a long time.3 month chart. Spread the word. @ASX_IHL
Trump admin via RFK, Jr. will be a renaissance for psychedelic drugs which have been curb stomped by the Biden FDA.
Look at tickers MNMD, ATAI, CYBN
https://t.co/PiHd0j9x13
FDA’s war on public health is about to end. This includes its aggressive suppression of psychedelics, peptides, stem cells, raw milk, hyperbaric therapies, chelating compounds, ivermectin, hydroxychloroquine, vitamins, clean foods, sunshine, exercise, nutraceuticals and anything else that advances human health and can't be patented by Pharma. If you work for the FDA and are part of this corrupt system, I have two messages for you: 1. Preserve your records, and 2. Pack your bags.
🆕 Joel Latham, CEO of Incannex Healthcare, discusses IHL-42X, a proprietary treatment combination for patients with #obstructivesleepapnea. #OSA#sleepdisorders@ASX_IHL
📺 Watch Now: https://t.co/QtC7CGfQOu
Excited to share tomorrow's post on how cannabis can help prevent cancer by inhibiting angiogenesis! This is crucial information that isn't discussed openly yet. Subscribe now for first access: https://t.co/ot4jgRnv0E 🌿✨
#CancerPrevention#CannabisScience#StayInformed
I gave talks on down-scheduling downunder, our Monash Psilocybin Therapist Study, and primary outcome data from our Psilocybin for Generalised Anxiety Disorder trial (for the first time!). Big shout out to the brilliant people in our Lab - the work I present is a team effort!
Just back from a fantastic time in Holland at #ICPR2024 hosted by @OPEN_fndn. Wonderful to connect with so many friends and colleagues from around the world, and present multiple times! Many thanks to the OPEN crew for putting on such a great event!
@ASX_IHL, a pharmaceutical company focused on developing medicinal #cannabinoid pharmacotherapies and psychedelic #medicine therapies, has commenced patient dosing in its phase 2/3 clinical trial to evaluate the safety and efficacy of IHL-42X for treating obstructive #SleepApnea (OSA).
Check it out: https://t.co/zgTdoIBMXy
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
$IXHL $PSIL
https://t.co/finZPc4Yyz
@daviddinenberg The FDA has approved several drugs that contain individual cannabinoids. $IXHL (42x) is a novel cannabinoid combination product for the treatment of Obstructive Sleep Apnoea (OSA).
currently in phase 2b trials https://t.co/0cYusTyoAy